Diabetic macular oedema: clinical risk factors and emerging genetic influences

Clinical and Experimental Optometry

Volumn 100, Issue 6, 2017, Pages 569-576

  Liu, Ebony ^a   Craig, Jamie E ^a   Burdon, Kathryn ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

diabetes; retinopathy

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

COMPLICATION; DIABETIC RETINOPATHY; GENETIC PREDISPOSITION; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACULAR EDEMA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; VISUAL DISORDER;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; GENETIC PREDISPOSITION TO DISEASE; GLYCATED HEMOGLOBIN A; HUMANS; MACULAR EDEMA; RISK FACTORS; VISION DISORDERS;

EID: 85019680206     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/cxo.12552     Document Type: Review

References (114)

1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015; 2: 17.
2. Yau JW, Rogers SL, Kawasaki R et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556–564.
3. Coucha M, Elshaer SL, Eldahshan WS et al. Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. Middle East Afr J Ophthalmol 2015; 22: 135–144.
4. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 2015; 122: 1375–1394.
5. Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. Br J Ophthalmol 2016; 100: 1596–1604.
6. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796–1806.
7. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115: 1447–1449.
8. Boyer DS, Yoon YH, Belfort R et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904–1914.
9. Deloitte Access Economics Pty Ltd. The Economic Impact of Diabetic Macular Oedema in Australia, 2015. Available at: http://www.mdfoundation.com.au/resources/Final_report_Economic_Impact_of_DME_in_Australia.pdf [Accessed 20 March 2017].
10. Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. Diabetes 1982; 31: 19–21.
11. Pyke DA, Tattersall RB. Diabetic retinopathy in identical twins. Diabetes 1973; 22: 613–618.
12. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46: 1829–1839.
13. Arar NH, Freedman BI, Adler SG et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci 2008; 49: 3839–3845.
14. Hallman DM, Huber JC Jr, Gonzalez VH et al. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care 2005; 28: 1163–1168.
15. Hietala K, Forsblom C, Summanen P et al. Heritability of proliferative diabetic retinopathy. Diabetes 2008; 57: 2176–2180.
16. Rema M, Saravanan G, Deepa R et al. Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients. Diabet Med 2002; 19: 910–916.
17. Zhang X, Gao Y, Zhou Z et al. Familial clustering of diabetic retinopathy in Chongqing, China, type 2 diabetic patients. Eur J Ophthalmol 2010; 20: 911–918.
18. Kaidonis G, Mills RA, Landers J et al. Review of the prevalence of diabetic retinopathy in Indigenous Australians. Clin Experiment Ophthalmol 2014; 42: 875–882.
19. Varma R, Bressler NM, Doan QV et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 2014; 132: 1334–1340.
20. Hosseini SM, Boright AP, Sun L et al. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet 2015; 134: 247–257.
21. Chu CJ, Johnston RL, Buscombe C et al. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology 2016; 123: 316–323.
22. Loewenstein A, Zur D. Postsurgical cystoid macular edema. Dev Ophthalmol 2010; 47: 148–159.
23. Diep TM, Tsui I. Risk factors associated with diabetic macular edema. Diabetes Res Clin Pract 2013; 100: 298–305.
24. Behl T, Kaur I, Kotwani A. Implication of oxidative stress in progression of diabetic retinopathy. Surv Ophthalmol 2016; 61: 187–196.
25. Fullerton B, Jeitler K, Seitz M et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014; CD009122.
26. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136–145.
27. Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care 2016; 39: 1089–1100.
28. Chou TH, Wu PC, Kuo JZ et al. Relationship of diabetic macular oedema with glycosylated haemoglobin. Eye (Lond) 2009; 23: 1360–1363.
29. Klein R, Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7–16.
30. Hsu CR, Chen YT, Sheu WH. Glycemic variability and diabetes retinopathy: a missing link. J Diabetes Complications 2015; 29: 302–306.
31. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527–532.
32. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520–526.
33. Kayykcyolu O, Ozmen B, Seymenoglu G et al. Macular edema in unregulated type 2 diabetic patients following glycemic control. Arch Med Res 2007; 38: 398–402.
34. Guan K, Hudson C, Wong T et al. Retinal hemodynamics in early diabetic macular edema. Diabetes 2006; 55: 813–818.
35. Klein R, Myers CE, Lee KE et al. 15-year cumulative incidence and associated risk factors for retinopathy in nondiabetic persons. Arch Ophthalmol 2010; 128: 1568–1575.
36. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317 (7160): 703–713.
37. Beulens JW, Patel A, Vingerling JR et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009; 52: 2027–2036.
38. Chang CH, Chuang LM. Effects of medical therapies on retinopathy progression in type 2 diabetes: Is blood pressure control the lower the better? J Diabetes Investig 2011; 2: 101–103.
39. Do DV, Wang X, Vedula SS et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 2015; CD006127.
40. Das R, Kerr R, Chakravarthy U et al. Dyslipidemia and Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmology 2015; 122: 1820–1827.
41. Therapeutic Goods Administration. Australian Public Assessment Report for fenofibrate, 2015. Available at: https://www.tga.gov.au/node/288291. [Accessed 20 March 2017].
42. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687–1697.
43. Chew EY, Davis MD, Danis RP et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology 2014; 121: 2443–2451.
44. Lachin JM, Genuth S, Nathan DM et al. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—revisited. Diabetes. 2008; 57: 995–1001.
45. Klein R. The epidemiology of diabetic retinopathy. In: Duh E, ed. Diabetic Retinopathy. Totowa, New Jersey: Humana Press, 2008. p 67–107.
46. Hampton BM, Schwartz SG, Brantley MA Jr et al. Update on genetics and diabetic retinopathy. Clin Ophthalmol 2015; 9: 2175–2193.
47. Kwak SH, Park KS. Genetic studies on diabetic microvascular complications: focusing on genome-wide association studies. Endocrinol Metab (Seoul) 2015; 30: 147–158.
48. Hammes HP, Lin J, Bretzel RG et al. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47: 401–406.
49. Funatsu H, Noma H, Mimura T et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116: 73–79.
50. Stevens A, Soden J, Brenchley PE et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63: 812–816.
51. Xie XJ, Yang YM, Jiang JK et al. Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk: a meta-analysis. J Diabetes 2016; doi: 10.1111/1753-0407.12480.
52. Han L, Zhang L, Xing W et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case–control studies. J Diabetes Res 2014; 2014: 805801.
53. Qiu M, Xiong W, Liao H et al. VEGF -634G > C polymorphism and diabetic retinopathy risk: a meta-analysis. Gene 2013; 518: 310–315.
54. Lu Y, Ge Y, Shi Y et al. Two polymorphisms (rs699947, rs2010963) in the VEGFA gene and diabetic retinopathy: an updated meta-analysis. BMC Ophthalmol 2013; 13: 56.
55. Zhao T, Zhao J. Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2010; 90: 45–53.
56. Zeng Y, Dai F, Yang K et al. Association between a vascular endothelial growth factor gene polymorphism (rs2146323) and diabetic retinopathy: a meta-analysis. BMC Ophthalmol 2015; 15: 163.
57. Wang H, Cheng JW, Zhu LS et al. Meta-analysis of association between the -2578C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians. Ophthalmic Res 2014; 52: 1–8.
58. Gong JY, Sun YH. Association of VEGF gene polymorphisms with diabetic retinopathy: a meta-analysis. PLoS One 2013; 8: e84069.
59. Awata T, Kurihara S, Takata N et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005; 333: 679–685.
60. El-Shazly SF, El-Bradey MH, Tameesh MK. Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes. Clin Experiment Ophthalmol 2014; 42: 369–378.
61. Abhary S, Burdon KP, Gupta A et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 5552–5558.
62. Zhao LQ, Zhu H, Zhao PQ et al. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011; 95: 1216–1222.
63. Puddu A, Sanguineti R, Durante A et al. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol Vis 2012; 18: 2509–2517.
64. Kaidonis G, Burdon KP, Gillies MC et al. Common sequence variation in the VEGFC gene is associated with diabetic retinopathy and diabetic macular edema. Ophthalmology 2015; 122: 1828–1836.
65. Inomata Y, Hirata A, Takahashi E et al. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 2004; 15: 877–879.
66. Tong Z, Yang Z, Patel S et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidne y complications. Proc Natl Acad Sci U S A 2008; 105: 6998–7003.
67. Song Q, Zhang Y, Wu Y et al. Association of erythropoietin gene polymorphisms with retinopathy in a Chinese cohort with type 2 diabetes mellitus. Clin Exp Ophthalmol 2015; 43: 544–549.
68. Fan Y, Fu YY, Chen Z et al. Gene-gene interaction of erythropoietin gene polymorphisms and diabetic retinopathy in Chinese Han. Exp Biol Med (Maywood) 2016; 241: 1524–1530.
69. Abhary S, Burdon KP, Casson RJ et al. Association between erythropoietin gene polymorphisms and diabetic retinopathy. Arch Ophthalmol 2010; 128: 102–106.
70. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol 1999; 14: 233–239.
71. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991; 88: 4651–4655.
72. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992; 262: H611–H615.
73. Haverkamp S, Kolb H, Cuenca N. Endothelial nitric oxide synthase (eNOS) is localized to Muller cells in all vertebrate retinas. Vision Res 1999; 39: 2299–2303.
74. Zhao S, Li T, Zheng B et al. Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms in association with diabetic retinopathy susceptibility: a meta-analysis. Ophthalmic Genet 2012; 33: 200–207.
75. Uthra S, Raman R, Mukesh BN et al. Intron 4 VNTR of endothelial nitric oxide synthase (eNOS) gene and diabetic retinopathy in type 2 patients in southern India. Ophthalmic Genet 2007; 28: 77–81.
76. Awata T, Neda T, Iizuka H et al. Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes. Diabetes Care 2004; 27: 2184–2190.
77. Fukai T. Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011; 15: 1583–1606.
78. Hunt JV WS. Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Radic Res Commun 1991; 12–13: 115–123.
79. Nomiyama T, Tanaka Y, Piao L et al. The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. J Hum Genet 2003; 48: 138–141.
80. Lee SJ, Choi MG, Kim DS et al. Manganese superoxide dismutase gene polymorphism (V16A) is associated with stages of albuminuria in Korean type 2 diabetic patients. Metabolism 2006; 55: 1–7.
81. Mollsten A, Marklund SL, Wessman M et al. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes 2007; 56: 265–269.
82. Tian C, Fang S, Du X et al. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia 2010; 54: 803–822.
83. Shimoda-Matsubayashi S MH, Kobayashi T, Nakagawa-Hattori Y et al. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 1996; 226: 561–565.
84. Lee SJ, Choi MG. Association of manganese superoxide dismutase gene polymorphism (V16A) with diabetic macular edema in Korean type 2 diabetic patients. Metabolism 2006; 55: 1681–1688.
85. Teter B, LaDu MJ, Sullivan PM et al. Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain. Neuroreport 2016; 27: 791–795.
86. Errera FI, Silva ME, Yeh E et al. Effect of polymorphisms of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazilian patients. Braz J Med Biol Res 2006; 39: 883–888.
87. Shcherbak NS. Apolipoprotein E gene polymorphism is not a strong risk factor for diabetic nephropathy and retinopathy in Type I diabetes: case–control study. BMC Med Genet 2001; 2: 8.
88. Santos A, Salguero ML, Gurrola C et al. The epsilon4 allele of apolipoprotein E gene is a potential risk factor for the severity of macular edema in type 2 diabetic Mexican patients. Ophthalmic Genet 2002; 23: 13–19.
89. Chew EY, Klein KM, Ferris FL 3rd et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Arch Ophthalmol 1996; 114:1079–1084.
90. Bakbak B, Ozturk BT, Zamani AG et al. Association of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration. Curr Eye Res 2016; 41: 862–866.
91. Mastropasqua R, Toto L, Cipollone F et al. Role of microRNAs in the modulation of diabetic retinopathy. Prog Retin Eye Res 2014; 43: 92–107.
92. Kowluru RA, Koppolu P, Chakrabarti S et al. Diabetes-induced activation of nuclear transcriptional factor in the retina, and its inhibition by antioxidants. Free Radic Res 2003; 37: 1169–1180.
93. Taganov KD, Boldin MP, Chang KJ et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006; 103: 12481–12486.
94. Kern TS. Interrelationships between the retinal neuroglia and vasculature in diabetes. Diabetes Metab J 2014; 38: 163–70.
95. Mortuza R, Feng B, Chakrabarti S. miR-195 regulates SIRT1-mediated changes in diabetic retinopathy. Diabetologia 2014; 57: 1037–1046.
96. McAuley AK, Dirani M, Wang JJ et al. A genetic variant regulating miR-126 is associated with sight threatening diabetic retinopathy. Diab Vasc Dis Res 2015; 12: 133–138.
97. Kaidonis G, Gillies MC, Abhary S et al. A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetol 2016; 53: 643–650.
98. Jazdzewski K, Murray EL, Franssila K et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008; 105: 7269–7274.
99. Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405–1407.
100. Tashimo A, Mitamura Y, Nagai S et al. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. Diabet Med 2004; 21: 1292–1297.
101. Mitamura Y, Takeuchi S, Yamamoto S et al. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy. Jpn J Ophthalmol 2002; 46: 218–221.
102. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259: 344–348.
103. Dong L, Lv XY, Wang BJ et al. Association of monocyte chemoattractant protein-1 (MCP-1)2518A/G polymorphism with proliferative diabetic retinopathy in northern Chinese type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1921–1926.
104. Katakami N, Matsuhisa M, Kaneto H et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2010; 89: e9–12.
105. Jeon HJ, Choi HJ, Park BH et al. Association of monocyte chemoattractant protein-1 (MCP-1) 2518A/G polymorphism with proliferative diabetic retinopathy in Korean type 2 diabetes. Yonsei Med J 2013; 54: 621–625.
106. Gao BB, Clermont A, Rook S et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007; 13: 181–188.
107. Kita T, Clermont AC, Murugesan N et al. Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes 2015; 64: 3588–3599.
108. Abhary S, Burdon KP, Gupta A et al. Diabetic retinopathy is not associated with carbonic anhydrase gene polymorphisms. Mol Vis 2009; 15: 1179–1184.
109. Dedania VS, Grob S, Zhang K et al. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration. Retina 2015; 3: 381–391.
110. Kauppinen A, Paterno JJ, Blasiak J et al. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 2016; 73: 1765–1786.
111. Lazzeri S, Nardi M, Bocci G. Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? Pharmacogenomics 2013; 14: 1239–1242.
112. Agarwal A, Sarwar S, Sepah YJ et al. What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era? Curr Opin Ophthalmol 2015; 26: 177–183.
113. Singh RP, Habbu K, Ehlers JP et al. The impact of systemic factors on clinical response to ranibizumab for diabetic macular edema. Ophthalmology 2016; 123: 1581–1587.
114. Abedi F, Wickremasinghe S, Richardson AJ et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 2013; 120: 115–121.